Background. Sepsis induces microvascular inflammation and production of the vasodilator nitric oxide (NO) via endothelial and inducible nitric oxide synthase (eNOS or NOS III and iNOS or NOS II). Statins are cholesterol-lowering drugs; however, they also attenuate inflammation. This study aimed to determine whether pravastatin protected against sepsis-induced hypotension, loss of vascular tone, and microvascular inflammation via NOS pathways.
Sepsis is the major cause of death in intensive care units in the UK. 1 The pathophysiological response to sepsis involves the release of pro-inflammatory cytokines and vasoactive agents such as the vasodilator nitric oxide (NO), 2 which contributes to sepsis-induced decreases in arterial pressure. NO is synthesized from L-arginine in endothelial cells, either by calcium-dependent endothelial nitric oxide synthase (NOS III) or by calcium-independent inducible NOS (NOS II). NO then diffuses into adjacent vascular smooth muscle cells, activating soluble guanyl cyclase, producing cyclic guanosine 5 0 monophosphate to induce vessel relaxation via protein kinase G. 3 Sepsis is often modelled in laboratory studies using animals exposed to a component of Gram-negative bacteria, lipopolysaccharide (LPS), or by faecal peritonitis initiated by caecal ligation and puncture (CLP). LPS can be given at non-lethal doses that allow dissection of mechanisms of inflammation during sepsis, or more correctly, endotoxaemia. In the first few hours, NOS II and NOS III increases 4 5 and the resulting increase in NO is bactericidal, but can also be detrimental because it induces hypotension and inflammation. 2 After prolonged exposure to LPS (6 -48 h), there appears to be a decrease in NOS III, 5 6 including the sequestration of NOS III into intracellular stores via caveolin-1. 7 Activation of mechanisms that increase NOS III may be beneficial, as previous studies during endotoxaemia demonstrated that decreased capillary blood flow was reversed by stimulation of NOS III. 8 After CLP, survival also improved in mice over-expressing Akt, which is a signalling molecule for NOS III. 9 Statins are lipid-lowering drugs which act by inhibiting hepatic conversion of 3-hydroxy-3-methyl-glutaryl-CoA reductase (the rate-controlling enzyme of the mevalonate pathway, the metabolic pathway that produces cholesterol). However, statins also have been shown to have antiinflammatory properties. 10 Statins are hydrophilic (pravastatin and rosuvastatin) or lipophilic (atorvastatin, simvastatin, and fluvastatin) and there is evidence that the different types may have different actions. 11 This study investigated the potential beneficial microvascular effects of pravastatin, which is known to reduce mortality during sepsis in mice. 11 The hypothesis was that statins reduce microvascular complications during established sepsis via an increase in NOS III.
Methods

Animals and housing
Male Wistar rats (200-280 g, n¼18) were obtained from the Field Laboratories at the University of Sheffield, UK. All experiments were performed ethically in accordance with UK Home Office Law (Project Licence number 40/ 2809). Animals were held in the animal facilities for at least 1 week before experimental procedures, exposed to light on a 12:12 h cycle, maintained in a humidity-and temperature-controlled environment, maintained on 0.3% sodium, standard, pelleted, commercial diet, and allowed water ad libitum.
Intravital microscopy Surgery
Rats were anaesthetized with thiopental (induction, 30 mg kg 21 i.p.; maintenance, 40-90 mg kg 21 h 21 i.p.; Intra-Vital Sodium, Rhone-Poulenc Rourer, West Malina, UK), so the mesentery adjoining the ileum could be prepared for fluorescent intravital microscopy. 12 Arterial pressure and heart rate were stable throughout and no pedal reflex could be detected at any time. 12 Fluoroscein isothiocyanate (FITC) on celite (10%, A1628, Sigma, UK) was conjugated to bovine serum albumin [66 kDa BSA (98%), A7030, Sigma] as previously described. 13 The right jugular vein was also cannulated for administration of FITC-BSA (i.v. 0.02 g 100 g 21 body wt at T 230 ) and acetylcholine (ACh), along with the left carotid artery for computerized monitoring and continuous recording of mean arterial pressure (MAP) using WINDAQ (DI-400, DATAQ Instruments, Akron, OH, USA TM assigned an integer value to the brightness of the interstitial fluorescence based on an arbitrary grey scale ranging from 0 (black) to 244 (white). The fluorescent light intensity thus measured is proportional to the amount of leak. 12 Three small boxes were placed on the screen at random sites adjacent to small venules (,2 mm) to produce a mean of these values in each animal. The same sites were then used for repeated measurements.
Experimental groups
Vessels were studied between T 0 and T 240 min in: (i) saline (n¼6), (ii) LPS (infusions commenced at T 0 ), and (iii) LPSþpravastatin (200 mg kg 21 s.c., 18 and 3 h before T 0 ) groups (n¼18). The 4 h continuous low-dose infusion of LPS (150 mg kg 21 h
21
) was based on previous studies.
14 Rats were killed humanely using cervical dislocation at the end of the experiment. At the end of the procedure, cardiac puncture was also performed to obtain serum for measurement of nitrite (NO x assay). Mesenteric and lung tissue were removed and placed in formalin for 24 h, followed by undefined abbreviation IMS for up to 1 month before paraffin embedding and sectioning for immunohistochemistry (IHC).
Immunohistochemistry
Mesenteric tissue was removed from rats at the end of the experimental protocol and paraffin embedded for IHC with undefined abbreviation DAB in 5 mm sections. Sections were stained with either a polyclonal rabbit anti-human NOS II (1:2400, AbCam) or a rabbit anti-human NOS III (1:800, AbCam) primary antibody, which cross-react with rat tissue, with all experiments performed in one batch, so that intensities could be compared. Biotinylated goat antirabbit IgG was used as the secondary antibody and either lung (NOS III) or LPS-treated lung (NOS II) used as a positive control. Species-matched non-specific IgG was used as a negative control to ensure that antibody staining was specific.
Five vessel hot spots on each section were randomly selected on each slide (n¼6, 5 areas per animal) using a Chalkley grid 15 and analysis was blinded. The diameter of the grid was aligned next to a randomly selected vessel within the grid and following the advice of a consultant histopathologist, endothelial cells along the length of a 25 mm length of vessel graded as either: no staining, which gave an intensity of 0, up to the most intense staining, which had a value of 3. 16 Leucocytes were also counted and graded for intensity of staining (0 -3), within the area of the Chalkley grid ($39 mm 2 ).
Serum NO x levels
The StressXpress TM Nitric Oxide (total) Detection Kit was used according to the manufacturer's instructions, which quantifies total nitrite colorimetrically using the Griess reaction. Frozen serum was defrosted, diluted 1:10, and analysed in duplicate. The absorbance in each well between 540 and 570 nm was determined using a plate reader. The average net absorbance for each standard and sample was calculated by subtracting the average zero standard absorbance from the average absorbance for each standard and sample. This allowed nitrite levels to be calculated (NO x ), as an indicator of total NO production.
Statistical analysis
Arterial pressure, vessel diameters, and macromolecular leak are expressed as percentage changes from values at T 0 and compared with the LPS group unless otherwise stated. All data are presented as mean (SD). Intravital microscopy (IVM) data were analysed using two-way ANOVA, followed by the Bonferroni post hoc test to identify points of significance, apart from ACh responses (and nitrite/nitrate data), which were assessed using one-way ANOVA followed by Dunnett's test. IHC data were analysed using two-way ANOVA, followed by the Bonferroni test to identify points of significance. All statistical analyses were performed using Graphpad Prism version 5.0. Data were considered statistically significant at P,0.05.
Results
Arterial pressure 
NO endothelial-dependent relaxation
There were no significant changes in the diameters of arterioles or venules throughout the experiment in any group (Fig. 3) abolished after 4 h LPS [4.4 (7.4)%]. In the presence of LPS, vasodilation to ACh was restored by pravastatin [24.1 (7.9)%].
Expression of NOS II and NOS III
Endothelial expression NOS III expression was similar in both controls and LPS-treated tissue (Figs 4 and 5) . However, in the presence of LPS, pravastatin caused greater expression of NOS III than that observed in controls (P,0.05). LPS increased expression of inflammatory NOS II compared with controls, but increased NOS II expression was retained in the presence of pravastatin (P,0.05).
Leucocyte expression LPS decreased the numbers of leucocytes that expressed NOS II and NOS III compared with controls and this was partially restored to control levels by pravastatin, but did not reach significance (NOS III, P¼0.14; NOS II, P¼0.35) (Fig. 6) . However, no significant differences were detected between the intensities with either isoform. 
Serum (NO x ) concentration
Discussion
The rationale for performing this study was that the homeostatic balance of NOS II and NOS III is important during sepsis, contributing to cardiovascular complications 17 and agents such as statins, which alter the balance of NOS II: NOS III may have protective microvascular effects. In summary, these data showed that the widely prescribed hydrophilic statin, pravastatin, reduced macromolecular leak and leucocyte adhesion within the rat mesentery 2 -4 h after induction of endotoxaemia with LPS. It thus demonstrated potentially beneficial antiinflammatory effects within the microcirculation. Pravastatin also restored vessel relaxation to ACh in LPS-treated vessels. Concurrently, in LPS-treated tissue, pravastatin increased endothelial cell expression of NOS III. Taken together, pravastatin appears to exert beneficial effects on vessel tone and possibly arterial pressure, via an NOS III pathway. Previous studies have reported that pravastatin increases NOS III in endothelial cells 18 19 and our findings during endotoxaemia are in agreement with this. Pravastatin also reduced hind limb ischaemia in rats and restored blood flow by an NOS III mechanism, 20 but there is presently a lack of relevant mechanistic studies during sepsis with which to compare this particular statin.
If we consider endotoxaemia alone, previous studies have demonstrated that LPS causes hypotension, initially due to increased expression and function of NOS III, but this mechanism may become less important, or even down-regulated, as sepsis progresses. 5 21 22 In agreement with this, our IHC studies reported that LPS did not alter endothelial NOS III expression, but did abolish NOS III function, namely vessel relaxation to ACh. We therefore propose that in our model, there may be unaffected expression but reduced function due to alteration of pathways either up-or downstream of NOS III. There is some evidence that the latter may be due to changes in Akt phosphorylation during sepsis. 6 Lack of vessel responsiveness to ACh could also be the result of free radical production, but this is not something we could elucidate from the present study.
We demonstrated that pravastatin both increased relaxation to ACh and expression of NOS II during LPS administration. This is perhaps not surprising, as up-regulation of NOS III by statins may occur due to inhibition of the GTPase Rho, which depends upon geranylation by the isoprenoid geranylgeranyl-PP ( part of the HMCoA reductase pathway). 23 The interaction between Rho and NO is the focus of our ongoing research. However, in this study, despite endothelial NOS III expression being unaffected by endotoxaemia alone, our results indicate that by increasing NOS III beyond LPS and control concentrations pravastatin improves vessel responses to ACh. As pathways downstream are malfunctioning, greater levels of NOS III may be required for function of the vessel, thus pravastatin has a beneficial action. In agreement with our findings for endothelial cell expression, simvastatin and lovastatin have been shown to increase NOS III expression in cultured human saphenous vein endothelial cells. 24 Similarly, rosuvastatin up-regulated expression of mRNA for NOS III and protected from cerebral ischaemia in mice. 25 In agreement with our functional studies, fluvastatin also induced a 2-and 2.6-fold increase in NOS III and phosphorylated Akt, respectively, in rabbit mesenteric arteries. 6 On the other hand, incubation of platelets with pravastatin enhanced NOS III activity, but caused no significant change in platelet NOS III mRNA and protein concentration. 26 Nevertheless, it is difficult to compare NOS III signalling in endothelial cells and plasma/platelets, as demonstrated subsequently by our leucocyte data (see below).
Around 2 h after LPS administration, there may also be up-regulation of NOS II, which is known to be pro-inflammatory and associated with the production of tissue-damaging reactive oxygen species. 27 28 Hence, this isoform must also be considered when investigating NO mechanisms. In agreement with this, we also found that LPS increased serum levels of NO x . However, LPS increased NOS II expression remained unaffected by pravastatin. Surprisingly, however, serum NO x was reduced by pravastatin. Therefore, it could be proposed that the mesentery is behaving differently to other organs. Nevertheless, in our model of sepsis, at 4 h, pravastatin did not appear to be exerting anti-inflammatory effects in the mesentery via a reduction in NOS II.
We observed decreased leucocyte adhesion induced between 2 and 4 h of sepsis. Leucocyte adhesion is also indicative of inflammation as it is a prerequisite to migration into tissues, where leucocytes are able to release cytokine and oxygen free radicals responsible for tissue damage and multiple organ failure during sepsis. Pravastatin did not alter the numbers of leucocytes expressing NOS III. On the contrary, LPS decreased NOS II, but was restored by pravastatin. This unusual decrease in leucocyte NOS II during inflammation has previously been reported in a number of studies. 29 -31 NOS II knockout mice also have increased leucocyte-endothelial interactions in response to LPS. 30 31 Hence, although the pravastatin responses may be in accordance with an anti-inflammatory effect, there are different NOS mechanisms occurring in leucocytes, compared with endothelial cells that are beyond the scope of the current manuscript and require more detailed exploration by leucocyte biologists. In addition, it is always important to consider how expression is assessed as there were no significant differences in intensities detected between the groups.
This study also reports that pravastatin reduced LPS-induced leakage of FITC-BSA from post-capillary venules; hence, we have identified an important antiinflammatory effect that will contribute to reduced oedema and improvement of blood volume: a desirable property for recommending the use of statins in an intensive care setting. Interestingly, the effects on macromolecular leak occurred between 2 and 4 h when NOS III is up-regulated, despite pravastatin having no apparent effect on this isoform. Hence, further functional studies are probably required using specific and non-specific NOS inhibitors in vivo.
Using IHC, we also determined that LPS also caused up-regulation of NOS III in the endothelium, which is a known phenomenon and in agreement with previous literature. 32 However, we did not observe any reduction in endothelial cell expression of NOS II with pravastatin. This is in disagreement with previous studies, as chronic administration of simvastatin (10 mg kg 21 ) prevented aortic ring relaxation to LPS-induced NOS II. 33 Other studies have demonstrated that simvastatin decreases expression of NOS II in embryonic cardiac myoblasts in response to TNF-a and IL-1. 34 We therefore postulate that hydophilic statins, such as pravastatin, may have differential effects on NOS II (and NOS III) compared with lipophilic statins, such as simvastatin, and this will form the basis of our future investigations. Indeed, when several statins are compared for their effects on macrophage release of NO via NOS II (mediated by effects on NFkappa-B and STAT1 upstream of NOS II), there is a potency order of lovastatin.atorvastatin.fluvastatin. pravastatin. 35 Pravastatin also causes a more potent effect on NOS III expression compared with atorvastatin in rat lung. 24 Therefore, it may be that pravastatin exerts its beneficial effects via NOS III, whereas other statins have more potent effects on NOS II and it would useful to investigate other statins using our experimental model.
Despite our finding that pravastatin reduces macromolecular leak and leucocyte adhesion in the rat mesenteric microcirculation during sepsis, these data should be interpreted cautiously. First, reduced inflammation does not always result in reduced mortality, and mortality studies are required before we can conclude that pravastatin is beneficial during sepsis. Thus far, Merx and colleagues 36 have reported that simvastatin, atorvastatin, and pravastatin, but not fluvastatin, reduced mortality during CLP in rats. High levels of NOS III activation were also reported 20 h after CLP, highlighting potential differences in NOS III expression depending on the model used and the timing of NOS measurements. In addition, LPS is simulating septic conditions in a rat model and findings need to be repeated in both patients and the intensive care setting. It is important to note that our animals were anaesthetized and anaesthesia itself may alter microvascular responses to LPS. However, when studying the mesentery, i.v. rather than i.p. administration is preferred, and our previous work has identified that thiopental has fewer pro-/anti-inflammatory effects than propofol, fentanyl, or ketamine. 12 In conclusion, pravastatin reduces macromolecular leak and leucocyte adhesion and restores endothelial-dependent NO-mediated relaxation in the rat mesentery during LPS administration, in conjunction with increased endothelial expression of NOS III. More complex exploration of the intracellular NO pathway is warranted and it is important in future studies to determine whether other statins also have similar effects on NOS III during sepsis. Nevertheless, we provide experimental evidence that pravastatin given before operation can restore vascular tone and reduce microvascular inflammation during endotoxaemia and may therefore be useful for reducing inflammatory responses after surgery.
